-
Endpoints News2 weeks ago
Beam looks to accelerated approval for AATD base editing after promising update
Beam Therapeutics has provided a much-awaited update on its therapy that uses a form of CRISPR called base editing to precisely fix a single genetic typo...
-
Biotech Industry Intelligence2 weeks ago
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure
-
BioPharma Dive – AI / Data2 weeks agoSarepta sees early success with RNAi drugs from Arrowhead
Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.
-
GEN – Genetic Engineering & Biotechnology News2 weeks agoRentschler Highlights Milford Site Progress and Growth
During a gathering of Massachusetts political and company officials earlier this week, Rentschler Biopharma, a CDMO headquartered in Laupheim, Germany, cited the continued evolution and progress...
-
Uncategorized2 weeks ago
Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs
This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk...
-
Biotech Industry Intelligence2 weeks ago
Novo reports more triple-G data from China; Grifols plots IPO for biopharma unit
Novo reports more triple-G data from China; Grifols plots IPO for biopharma unit
-
AI & Machine Learning in Biotechnology2 weeks agoSTAT+: Sarepta Therapeutics shares rise on early promise for rare disease drugs
Sarepta Therapeutics’ next crop of medicines for muscular dystrophy appear to be safe and effective in early clinical trials, the company said, a positive though incremental...
-
Fierce Biotech2 weeks ago
FDA approves Denali’s Hunter syndrome drug, handing rare disease community a win
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates.
-
Uncategorized2 weeks ago
UCB Investing $2B To Build Manufacturing Facility in Georgia
The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising...
-
GEN – Genetic Engineering & Biotechnology News2 weeks agoXaira’s First Virtual Cell Model Is Largest To-Date, Toward Complex Biology
Billion dollar-backed AI drug developer, Xaira Therapeutics, has recently released the largest virtual cell model to-date to predict how cells respond to genetic perturbations in unseen biological contexts. The team asserts that accurately predicting transcriptome-level effects is a...
